Defiance BMNR Option Income ETF (YBMN)

The Defiance BMNR Option Income ETF (ticker: YBMN) is an exchange-traded fund that holds a basket of biomedical and healthcare company stocks and systematically sells call options against those holdings to capture option premium as income, trading away upside above a strike price in exchange for higher cash distributions.

“The fund is a bet that biomedical winners will trade in a range—not explode past a strike, but not collapse either.”

The covered-call playbook

YBMN holds a curated portfolio of biotechnology and healthcare companies—a sector known for both high volatility and the strong performance of successful drug developers and medical-device makers. Rather than simply hold those stocks and collect dividends (where applicable), the fund layer on top a systematic options strategy.

Every month, or on a set schedule, the fund sells call options on its entire holdings. A call option gives a buyer the right to purchase the underlying stock at a fixed price—the “strike”—on or before expiration. By selling calls, the fund receives a cash premium, which it pays out to shareholders as distribution income. The trade-off is clear: if a stock rises above the strike price and gets called away, the fund owner misses that upside and has to sell at the strike rather than the higher market price.

This is not exotic or new; covered-call writing is a textbook income strategy used by conservative funds, insurance companies, and individual investors. Defiance, the fund issuer, applies it systematically to a focused healthcare sector, so investors get not just option income but also thematic stock exposure to an industry many believe has structural tailwinds.

The BMNR component and holdings

The fund’s holdings focus on companies involved in biomedics and novel medicines—small-cap and mid-cap biotechs, drug developers, medical device makers, and laboratory-reagent suppliers. The acronym BMNR likely refers to an index or basket rule that selects such names. Unlike a broad healthcare ETF that includes hospitals, insurance, pharma giants, and distribution, YBMN concentrates on the research and development frontier.

Because it is a narrow sector, the portfolio can be held with fewer than 50 names, sometimes as few as 30–40. Each position is sized to let the fund sell a meaningful proportion of shares as call options without being forced to call away more than a fraction of the stake. The fund rebalances periodically, usually quarterly, to refresh the lineup and maintain focus on names still deemed likely to trade in the target range.

Income and distributions

The principal appeal of YBMN is income. Call options sold at the money or slightly out of the money generate premium that, in a calm biotech sector, can add 3–8% annualised yield above whatever dividend the underlying stocks naturally pay. That premium is paid out to shareholders, typically as monthly or quarterly distributions, boosting the total yield relative to owning the biotech stocks outright.

This comes with a cost: the fund forgoes upside. If a biotech name doubles after the fund sells calls at a 10% out-of-the-money strike, the fund’s shareholders capture the 10% move to the strike but miss the additional 90% surge. In sectors known for explosive runners and multi-baggers, this is a real drag; a fund owner banking on a biotech moonshot is in the wrong fund.

Risks and the true profile

The covered-call structure means YBMN is less volatile than the underlying biotech stocks. The options provided a floor of sorts—the strike price effectively caps downside impact—but does not eliminate it. If biotechs crater, the fund falls too, and the option premium collected beforehand does not fully cushion the fall.

Call expiration timing creates a mechanical risk. If the fund sells monthly call options and a biotech stock gaps up sharply before expiration, the fund misses most of the move. If the gap happens after expiration, the fund has reset at a higher level and has new premium to collect. This timing is path-dependent and unpredictable, though over long stretches the law of large numbers smooths out temporary advantages and disadvantages.

Sector concentration is significant. Biotechnology is inherently volatile; small-cap names are illiquid; success is binary (drug approval or failure). A fund holding only biotech names is not diversified across the economy. If the sector underperforms for years, YBMN underperforms too.

The fund also carries operational risk. Defiance must monitor options markets, execute the selling at appropriate prices, and manage the mechanics of assignment when calls are exercised. In a dislocation or during a market panic when option markets themselves become dysfunctional, this process can break down or become costly.

Who this is for

YBMN is for income-focused investors who are comfortable with the biomedical sector, expect it to trade sideways to modestly higher (not in explosive runs), and value reliable distributions over capital appreciation. It suits retirement portfolios or funds seeking predictable cash flow. It is not for growth investors betting on sector explosions or for those uncomfortable with options mechanics.

The fund is also suited to investors who believe in biotech but want downside cushion; the covered-call structure provides a modest dampener on volatility, even if it sacrifices upside.

How to research YBMN

Start with the fund’s prospectus and fact sheet, which detail the call-selling mechanism, the strike-selection rules, the rebalancing schedule, and the distribution frequency. The prospectus should also explain what happens if a position is called away mid-month or if a stock experiences a large gap move.

Compare the fund’s yield—the distribution rate—to the yield of an unleveraged biotech index ETF and to the current option premium available in the markets. If options are trading rich (high premium), YBMN will produce high yield; if options are cheap, yield will be muted. This is a market-timing factor beyond the fund’s control.

Monitor the fund’s holdings report for concentration. If a single biotech name has grown to more than 3–5% of the portfolio, the fund’s results are increasingly dependent on that one stock’s behaviour. Also track which calls are assigned (called away) and which renew—this reveals whether the fund’s biotech picks are indeed trading in the expected range or are instead runaway winners the fund is forced to sell cheaply.